ECS Botanics
ECS Botanics is an ASX-listed Australian medicinal cannabis company that cultivates organic, sun-grown cannabis and manufactures PIC/S GMP-certified products (dried flower, capsules, pastilles, vapes) for B2B pharmaceutical partners and B2C patients across Australia, Germany, the UK, and New Zealand.
- Company typePublic
- Founded2018
- HeadquartersMurrabit, Australia
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What ECS Botanics does
ECS Botanics Holdings Ltd (ASX: ECS) is a vertically integrated Australian medicinal cannabis company founded in 2018 and headquartered in northwestern Victoria, near the Murray River. The company cultivates cannabis organically in living soil under the Australian sun and manufactures pharmaceutical-grade dosage formats under PIC/S GMP certification (EU-GMP equivalent). It is the only certified organic Australian cultivator operating at this certification tier, with a product range spanning dried flower (15-30% THC, Sativa and Indica), soft-gel capsules, pastilles (sugar-free and vegan options), cannabis extracts for oil formulation, and THC vape products. Underlying technology includes regenerative agriculture practices, terpene-preserving drying and curing processes, and PIC/S GMP-controlled post-harvest handling that treats cannabis flower as an active pharmaceutical ingredient.
ECS operates a hybrid B2B and B2C commercial model. The B2B segment supplies white-label and branded medicinal cannabis to pharmaceutical distributors and wholesalers in Australia, Germany, the UK, and New Zealand under multi-year binding offtake agreements totaling over A$60M, including a A$24M five-year MediCann Health deal, a A$10.2M three-year Entoura agreement, a A$9.9M three-year Ilios Santé GmbH contract, and a 10-year Sun Pharma toll processing arrangement. The B2C segment, launched in 2024, sells directly to patients through 540 prescribing medical practitioners and pharmacy dispensing, generating A$2.2M (46% of total revenue) in Q3 FY25. In September 2024, ECS secured an eight-year licensing and marketing agreement with California cannabis brand TerpHogz for distribution of Original Z genetics across Australia, the UK, Germany, and New Zealand. The company divested non-core Tasmanian assets (TasCo, A$3M) and its hemp food business (A$250K) in 2024 to focus on its vertically integrated Victorian GMP operation.
ECS Botanics firmographics
Firmographics- Name
- ECS Botanics
- Legal name
- ECS Botanics Holdings Ltd
- Website
- https://ecs-botanics.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ECS Botanics is an ASX-listed Australian medicinal cannabis company that cultivates organic, sun-grown cannabis and manufactures PIC/S GMP-certified products (dried flower, capsules, pastilles, vapes) for B2B pharmaceutical partners and B2C patients across Australia, Germany, the UK, and New Zealand.
- Ownership category
- akta.pro rank
Where ECS Botanics is headquartered
LocationHeadquarters
- HQ city
- Murrabit
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
ECS Botanics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Medicinal Cannabis Product Sales: ECS manufactures and supplies pharmaceutical-grade medicinal cannabis in multiple dosage formats including organically grown dried flower (15-30% THC with Sativa and Indica dominance), soft-gel capsules, pastilles (sugar-free and vegan), extracts, and THC vape products. Products are sold both under own brands (B2C) and as white-label B2B products.
- Offtake and Supply Agreements: ECS generates revenue through binding offtake agreements with distributors and retailers including MediCann Health ($24M/5-year deal), Entoura ($10.2M/3-year), Precision Pharmaceuticals ($1.7M), Ilios Santé GmbH Germany ($9.9M/3-year), and others. These contracts provide minimum volume commitments with potential for exceeding minimums.
- Licensing and Brand Royalties: ECS secured an eight-year licensing and marketing agreement with California cannabis brand TerpHogz in September 2024, positioning itself to launch iconic cannabis products globally including the Original Z genetics. Revenue generated from licensing arrangements and brand product sales.
- Contract Manufacturing (Tolling): ECS provides toll processing and manufacturing services for strategic partners, including a 10-year supply and toll processing agreement with Sun Pharma for cannabis biomass extraction. This leverages manufacturing capacity and expertise.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
ECS Botanics product offering
Product offeringCore offering
ECS Botanics cultivates organic, sun-grown medicinal cannabis in northwestern Victoria, Australia and manufactures pharmaceutical-grade dosage formats (dried flower 15-30% THC, soft-gel capsules, pastilles, extracts, THC vapes) to PIC/S GMP (EU-GMP equivalent) standards. Products are supplied both as B2B white-label and bulk API to pharmaceutical distributors and through B2C direct-to-patient sales via prescribing practitioners and partner pharmacies.
Product overview
ECS Botanics is a vertically integrated medicinal cannabis company that cultivates organic, sun-grown cannabis in Victoria, Australia and manufactures to EU-GMP (PIC/S GMP) standards. The company operates a B2B business model providing white-label cultivation and manufacturing services while also developing its own retail product line. The product portfolio includes dried flower (15-30% THC, Sativa and Indica varieties with new Californian genetics), soft-gel capsules, pastilles (sugar-free and vegan options), cannabis extracts for oil formulations, and THC vape products. The company has also licensed the TerpHogz California cannabis brand for distribution in Australia and international markets.
Differentiator
Problem solved
Functional benefit
Brands
- TerpHogz: Licensed California cannabis brand featuring Original Z genetics, launched under an eight-year licensing agreement in September 2024 for Australian and international markets including Germany, UK, and New Zealand.
- Murray Meds
Products and services
- Dried Flower Organically grown, sun-cultivated dried cannabis flower for inhalation, available in both Sativa and Indica dominance with 15-30% THC content and new Californian genetics. Suitable for medical use or further processing in GMP licensed extraction facilities.
- Soft-gel Capsules Pharmaceutical-standard capsules manufactured using high-quality cannabis extracts, delivering precise and consistent dosing in an oral format with predictable pharmacokinetics and 24-month stability.
- Pastilles (Gummies) Pre-measured oral dosage forms designed for ease of use and patient preference, manufactured under EU-GMP quality systems in sugar-free and vegan options for consistent dosing.
- Cannabis Extracts Resin extracted from ECS strains for the formulation of oils and other products. ECS works with strategic partners to formulate off-the-shelf and bespoke cannabinoid formulations.
- THC Vape Products Pharmaceutical-standard vape formulations manufactured using high-quality cannabis extracts to deliver consistent, reliable inhalation experience with rapid onset and precise dosing.
- White-Label Manufacturing Services B2B pharmaceutical manufacturing service providing cannabinoid products to strategic global partners in pharmaceutical-grade dosage formats including white-label products. Includes contract manufacturing (toll processing) such as the 10-year biomass extraction agreement with Sun Pharma.
- TerpHogz Licensed Cannabis Brand Licensed California cannabis brand featuring the Original Z genetics, launched under an eight-year licensing and marketing agreement for distribution across Australia, UK, Germany and New Zealand markets.
Quantifiable outcome
- 78% revenue surge with 60% increase in outdoor cultivation area
- +3 more outcomes
Companies that use ECS Botanics
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles2 records
ECS Botanics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ECS Botanics partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and major.
- Nimbus HealthcoreECS Botanics entered into a distribution partnership with Nimbus Health in Germany for medicinal cannabis products, supporting the company's European market expansion strategy.
- TerpHogzcoreECS secured an eight-year licensing and marketing agreement with TerpHogz, a renowned cannabis breeding group from Mendocino County, California. The partnership includes the Original Z genetics and positions ECS to launch TerpHogz products in Australia, UK, Germany, and New Zealand.
- RokshawmajorBinding offtake agreement with UK-based Rokshaw for supply of medicinal cannabis dried flower over three years.
- Ilios Santé GmbHcoreBinding three-year agreement for ECS to exclusively supply four medicinal cannabis strains to German licensed wholesaler with approval to import and distribute narcotics. Minimum revenue of $9.9 million over contract term.
- MediCann Healthcore$24 million five-year binding agreement to supply medicinal cannabis dried flower. Supply commenced January 2024 with over four tonnes of dried cannabis flower to be delivered. Builds on existing two-year contract.
- Entouracore$10.2 million three-year supply agreement for GMP medicinal cannabis dried flower. ECS supplies minimum three strains exclusive to Entoura. Entoura develops high-quality medicinal cannabis products and supports research.
- Sun PharmamajorCollaborative 10-year supply and toll processing agreement for cannabis biomass extraction. Sun Pharma is an Australia-based subsidiary of Sun Pharmaceutical Industries, the fourth largest specialty generic pharmaceutical company globally.
- The Armour GroupmajorThree-year supply agreement with London-based pharmaceuticals distribution company for sale and export of medicinal cannabis oils in UK and Germany.
- Releaf DispensariesmajorSupply deal for dried cannabis flower to Melbourne-based Releaf Group, Australia's first dedicated clinic and dispensary franchise group. Expected to generate approximately A$590,000 over 18-month term.
Scale indicators8 records
Recent moves8 records
Expansion highlights2 records
ECS Botanics competitors and assessment
Company assessmentDirect peers
- Little Green Pharma: ASX-listed Australian medicinal cannabis cultivator and manufacturer with EU-GMP certification, supplying both Australian patients and European markets (notably Germany). Directly comparable in business model — vertical cultivation + GMP manufacturing + B2B wholesale and B2C branded products.
- Cann Group: ASX-listed Australian medicinal cannabis company with cultivation, manufacturing, and domestic/international distribution. Closely comparable to ECS in regulatory positioning (TGA/PIC-S GMP) and Australian patient market focus, though at larger scale.
- Althea Group Holdings: Australian medicinal cannabis company (ASX:AGH) with proprietary branded product range sold through prescribers and pharmacies domestically, plus UK/European expansion. Highly comparable B2C prescriber-channel model and Australian patient focus.
- AusCann Group Holdings: ASX-listed Australian medicinal cannabis company focused on manufacturing, distribution, and clinical research of cannabinoid medicines. Comparable vertically integrated Australian manufacturer targeting similar prescriber and pharmacy channels.
- MGC Pharmaceuticals: Australian-listed medicinal cannabis company with European operations and focus on pharmaceutical-grade cannabinoid medicines for UK, EU, and Australian markets. Comparable GMP manufacturing and cross-jurisdictional distribution strategy.
- Cronos Australia: ASX-listed Australian medicinal cannabis distributor with branded patient products. Both an industry peer and an existing ECS offtake customer ($750K minimum contract), reflecting overlapping prescriber-channel positioning.
Emerging players
- Incannex Healthcare: ASX-listed cannabinoid and psychedelic medicine developer, focused on clinical research and pharmaceutical-grade cannabinoid therapies. Comparable Australian cannabis player with pharmaceutical orientation rather than pure cultivation.
Broad incumbents
- Tilray Brands: Global cannabis major with established operations across Canada, US, Europe, and Australia. Competes with ECS in international medicinal cannabis distribution and is significantly larger, but overlaps directly in EU-GMP flower and extract supply.
- Aurora Cannabis: Large Canadian cannabis producer with European GMP-certified operations serving Germany and other EU medical markets. Comparable EU-GMP positioning and Germany export ambition to ECS.
- Canopy Growth Corporation: Global cannabis major with medical cannabis operations in Canada, Germany, and Australia (via Spectrum Therapeutics). Overlaps with ECS in Australian patient channels and EU medical cannabis supply.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ECS Botanics social profiles
Digital presenceECS Botanics compliance and trust
Trust signalCompliance4 records
ECS Botanics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ECS Botanics leadership team
Management profileNumber of profiles
Profiles14 records
ECS Botanics subsidiaries and ownership
Company hierarchySubsidiaries1 record
ECS Botanics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ECS Botanics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ECS Botanics
What does ECS Botanics do?
ECS Botanics cultivates organic, sun-grown medicinal cannabis in northwestern Victoria, Australia and manufactures pharmaceutical-grade dosage formats (dried flower 15-30% THC, soft-gel capsules, pastilles, extracts, THC vapes) to PIC/S GMP (EU-GMP equivalent) standards. Products are supplied both as B2B white-label and bulk API to pharmaceutical distributors and through B2C direct-to-patient sales via prescribing practitioners and partner pharmacies.
Is ECS Botanics a public or private company?
ECS Botanics is a public company. It is classified as public and is currently operating.
When was ECS Botanics founded?
ECS Botanics was founded in 2018. It employs 11 to 50 people.
Where is ECS Botanics based?
ECS Botanics is headquartered in Murrabit, Australia, in the Oceania region.
How does ECS Botanics make money?
Four revenue lines are on record. Medicinal Cannabis Product Sales are the primary driver. The others are offtake and Supply Agreements, licensing and Brand Royalties and contract Manufacturing (Tolling).
Who are ECS Botanics's main competitors?
Direct peers on record are Little Green Pharma, Cann Group, Althea Group Holdings, AusCann Group Holdings, MGC Pharmaceuticals and Cronos Australia. Incannex Healthcare is listed as an emerging player. Broad incumbents are Tilray Brands, Aurora Cannabis and Canopy Growth Corporation.
Does ECS Botanics have an API?
No public API is recorded for ECS Botanics.